Anticancer drug(s) which does/do not suppress bone marrow ?
**Core Concept:** Anticancer drugs are substances used to treat cancer by interfering with cell division and growth. Some anticancer drugs suppress bone marrow, which is responsible for producing blood cells, while others do not.
**Why the Correct Answer is Right:**
Azacitidine is a hypomethylating agent that acts as a DNA analog and incorporates into DNA, inhibiting DNA methylation and disrupting DNA replication. This leads to cell cycle arrest, apoptosis, and differentiation of cancer cells. Azacitidine does not suppress bone marrow as much as other cytotoxic anticancer drugs.
**Why Each Wrong Option is Incorrect:**
Option A (Hydralazine) is an antihypertensive drug, not an anticancer agent.
Option B (Methotrexate) is an antimetabolite that interferes with purine and pyrimidine synthesis, leading to cell cycle arrest and apoptosis. However, methotrexate does suppress bone marrow.
Option C (Ibrutinib) is a Bruton's tyrosine kinase inhibitor used in the treatment of certain B-cell malignancies. Although it targets cancer cells, it also causes bone marrow suppression.
Option D (Thalidomide) is an immunomodulatory drug used in the treatment of multiple myeloma. It suppresses the immune system and can cause bone marrow suppression.
**Why the Correct Answer is Right:**
Azacitidine is a newer, more selective drug that targets cancer cells without causing significant bone marrow suppression, making it a better choice for treating cancer patients with decreased blood cell production due to prior chemotherapy or radiation therapy.
**Why Each Wrong Option is Incorrect:**
Option A (Hydralazine) is a calcium channel blocker that does not suppress bone marrow.
Option B (Methotrexate) is a cytotoxic drug that affects DNA synthesis, leading to bone marrow suppression.
Option C (Ibrutinib) is a Bruton's tyrosine kinase inhibitor that suppresses the immune system and can cause bone marrow suppression.
Option D (Thalidomide) is an immunomodulatory drug that suppresses the immune system and can cause bone marrow suppression.
**Clinical Pearl:** Understanding the pharmacology and side effect profiles of various anticancer drugs is crucial when choosing the most appropriate treatment for cancer patients, especially those with compromised bone marrow function. In this scenario, azacitidine presents a safer option for patients with decreased blood cell production, as it selectively targets cancer cells without causing significant bone marrow suppression.